Mirum Pharmaceuticals Company Leadership
MIRM Stock | USD 47.02 0.85 1.78% |
About 75% of Mirum Pharmaceuticals' corporate insiders are selling. The analysis of the overall insider sentiment regarding Mirum Pharmaceuticals suggests that many insiders are alarmed. Mirum Pharmaceuticals employs about 322 people. The company is managed by 13 executives with a total tenure of roughly 752 years, averaging almost 57.0 years of service per executive, having 24.77 employees per reported executive.
Insider Sentiment 25
Mostly Selling
Selling | Buying |
Latest Trades
2025-03-17 | Christopher Peetz | Disposed 27279 @ 44.21 | View | ||
2025-03-04 | Patrick J Heron | Acquired 1335 @ 45.57 | View | ||
2025-02-03 | Peter Radovich | Disposed 2627 @ 48.22 | View | ||
2025-01-24 | Peter Radovich | Disposed 3177 @ 47.92 | View | ||
2025-01-17 | Joanne Quan | Disposed 6969 @ 45.86 | View | ||
2025-01-07 | Jolanda Howe | Disposed 750 @ 42.82 | View | ||
2024-11-14 | Jolanda Howe | Disposed 2500 @ 47.1 | View | ||
2024-09-18 | Patrick J Heron | Acquired 115 @ 37.4 | View | ||
2024-09-06 | Patrick J Heron | Acquired 230 @ 41.58 | View | ||
2024-07-02 | Jolanda Howe | Disposed 375 @ 34 | View | ||
2024-06-24 | Pamela Vig | Disposed 30559 @ 34 | View | ||
2024-06-05 | Saira Ramasastry | Disposed 5000 @ 25.68 | View |
Monitoring Mirum Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Mirum |
Mirum Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Mirum Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Mirum will maintain a workforce of about 320 employees by April 2025.Mirum Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.0831) % which means that it has lost $0.0831 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3708) %, meaning that it created substantial loss on money invested by shareholders. Mirum Pharmaceuticals' management efficiency ratios could be used to measure how well Mirum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.17. At this time, Mirum Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 24th of March 2025, Non Current Assets Total is likely to grow to about 291.9 M, while Non Currrent Assets Other are likely to drop about 5.5 M.As of the 24th of March 2025, Common Stock Shares Outstanding is likely to drop to about 35.2 M. In addition to that, Net Loss is likely to drop to about (128.2 M)
Mirum Pharmaceuticals Workforce Comparison
Mirum Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,823. Mirum Pharmaceuticals holds roughly 322 in number of employees claiming about 8% of equities under Health Care industry.
Mirum Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (0.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.24.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.89 | 0.7577 |
|
|
Mirum Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mirum Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mirum Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mirum Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 1.0606 | 35 | 33 | 689,156 | 391,538 |
2024-12-01 | 2.0 | 4 | 2 | 3,158 | 5,000 |
2024-09-01 | 1.0 | 5 | 5 | 53,734 | 156,552 |
2024-06-01 | 5.25 | 21 | 4 | 152,796 | 71,118 |
2024-03-01 | 1.3846 | 18 | 13 | 536,772 | 27,496 |
2023-12-01 | 2.5 | 5 | 2 | 6,589 | 5,000 |
2023-09-01 | 1.0 | 10 | 10 | 349,703 | 43,592 |
2023-06-01 | 1.0938 | 35 | 32 | 457,002 | 18,527,273 |
2023-03-01 | 2.0 | 8 | 4 | 418,440 | 8,920 |
2022-12-01 | 2.0 | 6 | 3 | 35,408 | 300,000 |
2022-06-01 | 2.625 | 21 | 8 | 302,138 | 52,221 |
2021-12-01 | 1.3333 | 8 | 6 | 11,457 | 10,299 |
2021-09-01 | 1.75 | 7 | 4 | 97,750 | 166,000 |
2021-03-01 | 7.0 | 7 | 1 | 511,082 | 1,082 |
2020-12-01 | 6.5 | 13 | 2 | 44,524 | 29,167 |
2020-06-01 | 7.0 | 7 | 1 | 284,167 | 0.00 |
2019-12-01 | 1.0 | 1 | 1 | 100,000 | 0.00 |
2019-09-01 | 1.5758 | 52 | 33 | 63,557,806 | 445,671,693 |
Mirum Pharmaceuticals Notable Stakeholders
A Mirum Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mirum Pharmaceuticals often face trade-offs trying to please all of them. Mirum Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mirum Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher Peetz | CEO Director | Profile | |
Andrew McKibben | Strategic President | Profile | |
Peter MBA | Chief Officer | Profile | |
Ian Clements | Chief Officer | Profile | |
MSC MBA | Chief Officer | Profile | |
Jolanda Howe | Senior Controller | Profile | |
Eric MBA | Chief Officer | Profile | |
Paul Ross | Chief Officer | Profile | |
Joanne MD | Chief Officer | Profile | |
Pamela Vig | Chief Research | Profile | |
Erin Campany | Senior Resources | Profile | |
Vinita Kumar | Senior Quality | Profile | |
JeanLuc Girardet | Senior Operations | Profile |
About Mirum Pharmaceuticals Management Performance
The success or failure of an entity such as Mirum Pharmaceuticals often depends on how effective the management is. Mirum Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mirum management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mirum management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.21) | (0.22) | |
Return On Capital Employed | (0.16) | (0.17) | |
Return On Assets | (0.13) | (0.14) | |
Return On Equity | (0.39) | (0.37) |
Mirum Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Mirum Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mirum Pharmaceuticals within its industry.Mirum Pharmaceuticals Manpower Efficiency
Return on Mirum Pharmaceuticals Manpower
Revenue Per Employee | 1M | |
Revenue Per Executive | 25.9M | |
Net Loss Per Employee | 273.1K | |
Net Loss Per Executive | 6.8M | |
Working Capital Per Employee | 826.8K | |
Working Capital Per Executive | 20.5M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) | Revenue Per Share | Quarterly Revenue Growth 0.429 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.